Acquisitions - Fair Value of Purchase Consideration (Details) - BioDelivery Sciences International, Inc $ / shares in Units, $ in Thousands |
Mar. 22, 2022
USD ($)
$ / shares
shares
|
---|---|
Business Acquisition [Line Items] | |
Cash consideration for all outstanding shares of BDSI's common and preferred stock (103,265,298 shares acquired at $5.60 per share) | $ 578,118 |
Cash consideration paid to settle RSUs and in-the-money options | 28,309 |
Cash paid to settle BDSI debt | 63,004 |
Total purchase consideration | $ 669,431 |
Shares of common stock acquired | shares | 103,235,298 |
Share price (in dollars per share) | $ / shares | $ 5.60 |
X | ||||||||||
- Definition The amount of cash outflow to settle debt in a business combination. No definition available.
|
X | ||||||||||
- Definition Number of shares of equity interests issued or issuable to acquire entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. No definition available.
|
X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|